Do drugs offering only PFS maintain quality of life sufficiently from a patient's perspective? Results from AVALPROFS (Assessing the 'VALue' to patients of PROgression Free Survival) study.
Valerie JenkinsV FarewellS MayS CattL MatthewsV ShillingJ DicksonR SimcockL FallowfieldPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2018)
Maintaining QoL is vital to most patients with advanced cancer so minimising treatment-related side effects is essential. As side effect severity increased, drugs that controlled cancer for short periods were not viewed as worthwhile. Patients need to have the therapeutic aims of further anti-cancer treatment explained honestly and sensitively.